DCM
GMAB icon

DGS Capital Management’s Genmab GMAB Stock Holding History

DGS Capital Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$273K Sell
10,173
-8,030
-44% -$241K 0.04% 432
2025
Q4 		$561K Buy
18,203
+9,795
+116% +$305K 0.1% 190
2025
Q3 		$258K Buy
+8,408
New +$205K 0.05% 319

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

DGS Capital Management's GMAB Position: Q1 2026 in Review

DGS Capital Management reduced its Genmab (GMAB) stake by 44% in Q1 2026, selling an estimated $241K and leaving 10,173 shares worth $273K. The position accounts for 0.04% of the portfolio, ranked #432.

DGS Capital Management first reported a position in GMAB in Q3 2025 and has held it in 3 quarters since. The position peaked at $561K in Q4 2025. 275 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • DGS Capital Management held 10,173 shares of Genmab worth $273K as of Q1 2026.
  • DGS Capital Management sold 8,030 Genmab shares in Q1 2026, an estimated $241K.
  • Genmab made up 0.04% of DGS Capital Management's portfolio in Q1 2026, its #432 holding.
  • DGS Capital Management first reported a position in Genmab in Q3 2025 and has held it in 3 quarters since.
  • DGS Capital Management's Genmab position peaked at $561K in Q4 2025.
  • 275 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on DGS Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.